Wedbush Increases Earnings Estimates for Aprea Therapeutics

Aprea Therapeutics, Inc. (NASDAQ:APRE) – Stock analysts at Wedbush raised their Q3 2025 earnings per share estimates for shares of Aprea Therapeutics in a research note issued to investors on Tuesday, August 12th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($0.11) per share for the quarter, up from their prior forecast of ($0.14). Wedbush has a “Outperform” rating and a $11.00 price target on the stock. The consensus estimate for Aprea Therapeutics’ current full-year earnings is ($2.55) per share. Wedbush also issued estimates for Aprea Therapeutics’ Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.71) EPS, FY2026 earnings at ($0.55) EPS, FY2027 earnings at $0.33 EPS, FY2028 earnings at $1.13 EPS and FY2029 earnings at $2.20 EPS.

Aprea Therapeutics (NASDAQ:APRE) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.24. Aprea Therapeutics had a negative return on equity of 78.90% and a negative net margin of 1,645.01%. The company had revenue of $0.12 million for the quarter.

Aprea Therapeutics Stock Performance

Aprea Therapeutics stock opened at $1.69 on Friday. The stock’s 50 day simple moving average is $1.75 and its two-hundred day simple moving average is $2.06. The stock has a market cap of $9.85 million, a price-to-earnings ratio of -0.73 and a beta of 1.29. Aprea Therapeutics has a fifty-two week low of $1.41 and a fifty-two week high of $5.01.

Institutional Trading of Aprea Therapeutics

Several large investors have recently bought and sold shares of the company. Stonepine Capital Management LLC boosted its position in Aprea Therapeutics by 8.8% during the 4th quarter. Stonepine Capital Management LLC now owns 149,221 shares of the company’s stock valued at $491,000 after acquiring an additional 12,047 shares in the last quarter. LPL Financial LLC bought a new stake in Aprea Therapeutics during the 4th quarter valued at approximately $53,000. Finally, BNP Paribas Financial Markets bought a new stake in Aprea Therapeutics during the 4th quarter valued at approximately $43,000. 34.19% of the stock is owned by institutional investors.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.